Scientific work

Prof. Dr. Saadettin Kılıçkap

479 publications. The source of the information is stated next to each publication.

Back to profile

  1. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2305066 PMID 38263804 2 citations (Europe PMC) Source: OpenAlex

  2. Association of very deep prostate-specific antigen (PSA) decline with longer radiologic-progression-free survival (rPFS) in patients with metastatic castration-sensitive prostate cancer.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.e17074 Open-access full textSource: OpenAlex

  3. Immune Checkpoint Blockade Therapies Efficacy and Toxicity in Patients With Impaired Renal Function in Metastatic Bladder Cancer

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102228 PMID 39461025 1 citation (Europe PMC) Open-access full textSource: ORCID

  4. Objective Response Rate is a Surrogate Marker for Long-Term Overall Survival in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors

    Clinical Genitourinary Cancer, 2024

    DOI 10.1016/j.clgc.2024.102163 PMID 39126823 1 citation (Europe PMC) Source: ORCID

  5. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)

    Cancer Cell, 2024

    DOI 10.1016/j.ccell.2023.12.004 PMID 38181795 66 citations (Europe PMC) Open-access full textSource: ORCID

  6. COVID-19 pandemic: changes in cancer admissions

    BMJ Supportive and Palliative Care, 2024

    DOI 10.1136/bmjspcare-2020-002468 PMID 32665259 21 citations (Europe PMC) Open-access full textSource: ORCID

  7. Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial

    Nature Medicine, 2024

    DOI 10.1038/s41591-024-03008-4 PMID 38898120 29 citations (Europe PMC) Open-access full textSource: ORCID

  8. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study

    Current Medical Research and Opinion, 2024

    DOI 10.1080/03007995.2024.2359026 PMID 38809230 1 citation (Europe PMC) Open-access full textSource: ORCID

  9. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors

    Supportive Care in Cancer, 2024

    DOI 10.1007/s00520-024-08681-2 PMID 38937345 7 citations (Europe PMC) Open-access full textSource: ORCID

  10. Prevalence of EGFR Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study

    Journal of Thoracic Oncology, 2024

    DOI 10.1016/j.jtho.2024.06.008 PMID 38880172 53 citations (Europe PMC) Open-access full textSource: ORCID

  11. The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer

    Cancers, 2024

    DOI 10.3390/cancers16010156 PMID 38201583 8 citations (Europe PMC) Open-access full textSource: ORCID

  12. Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab

    JTO Clinical and Research Reports, 2024

    DOI 10.1016/j.jtocrr.2024.100675 PMID 39399157 11 citations (Europe PMC) Open-access full textSource: ORCID

  13. Vaccination attitudes and practices of physicians and nurses in adult oncology settings

    Journal of Research in Pharmacy, 2024

    DOI 10.29228/jrp.722 1 citation (OpenAlex) Open-access full textSource: ORCID

  14. Immune checkpoints blockade therapies' efficacy and toxicity in patients with impaired renal function in metastatic bladder cancer.

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.4_suppl.594 Open-access full textSource: OpenAlex

  15. 1271P Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC

    Annals of Oncology, 2024

    DOI 10.1016/j.annonc.2024.08.1328 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  16. Carcinoid Syndrome

    Springer eBooks, 2024

    DOI 10.1007/978-3-031-56968-5_29 Source: OpenAlex

  17. IMMUNOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CARCINOMA

    Turkiye Klinikleri eBooks, 2024

    DOI 10.5336/978-625-395-244-0_p31 Source: OpenAlex

  18. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

    The Oncologist, 2023

    DOI 10.1093/oncolo/oyad257 PMID 37676712 8 citations (Europe PMC) Open-access full textSource: OpenAlex

  19. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group ( TOG ) study

    Cancer Medicine, 2023

    DOI 10.1002/cam4.6869 PMID 38140782 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  20. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

    Journal of Cancer Research and Clinical Oncology, 2023

    DOI 10.1007/s00432-023-05190-3 PMID 37480524 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  21. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

    The Lancet Oncology, 2023

    DOI 10.1016/s1470-2045(23)00329-7 PMID 37591293 96 citations (Europe PMC) Source: OpenAlex

  22. Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis

    Journal of Thoracic Oncology, 2023

    DOI 10.1016/j.jtho.2023.08.017 PMID 37865896 29 citations (Europe PMC) Open-access full textSource: OpenAlex

  23. Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye

    Future Oncology, 2023

    DOI 10.2217/fon-2023-0518 PMID 38014519 Open-access full textSource: OpenAlex

  24. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.9022 3 citations (OpenAlex) Source: OpenAlex

  25. Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice

    Clinical Genitourinary Cancer, 2023

    DOI 10.1016/j.clgc.2022.11.019 PMID 36641357 2 citations (Europe PMC) Source: ORCID

  26. Adjuvant radiotherapy in the management of porocarcinoma with lymphatic micrometastasis

    Oncology in Clinical Practice, 2023

    DOI 10.5603/ocp.2023.0003 Open-access full textSource: ORCID

  27. Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group

    Current Problems in Cancer, 2023

    DOI 10.1016/j.currproblcancer.2023.101017 PMID 37845104 1 citation (Europe PMC) Open-access full textSource: ORCID

  28. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data

    Supportive Care in Cancer, 2023

    DOI 10.1007/s00520-023-08083-w PMID 37819422 171 citations (Europe PMC) Source: ORCID

  29. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

    International Journal of Cancer, 2023

    DOI 10.1002/ijc.34280 PMID 36082448 6 citations (Europe PMC) Open-access full textSource: ORCID

  30. Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study

    Supportive Care in Cancer, 2023

    DOI 10.1007/s00520-023-07652-3 PMID 36856870 7 citations (Europe PMC) Open-access full textSource: ORCID

  31. Intracerebral de novo arterio-venous malformations as a side effect of bevacizumab

    Journal of Oncology Pharmacy Practice, 2023

    DOI 10.1177/10781552231171113 PMID 37078175 Source: ORCID

  32. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

    Journal of Immunotherapy and Precision Oncology, 2023

    DOI 10.36401/jipo-23-3 PMID 38143956 6 citations (Europe PMC) Open-access full textSource: ORCID

  33. Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review,Radiothérapie dirigée sur les métastases de cancer du poumon non à petites cellules en échec sous inhibiteurs de la thyrosine kinase : cas clinique et revue de la littérature

    Cancer/Radiotherapie, 2023

    DOI 10.1016/j.canrad.2023.06.002 PMID 37827958 Source: ORCID

  34. Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events

    Future Oncology, 2023

    DOI 10.2217/fon-2023-0014 PMID 37449387 8 citations (Europe PMC) Open-access full textSource: ORCID

  35. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study

    Journal of Cancer Research and Clinical Oncology, 2023

    DOI 10.1007/s00432-022-04268-8 PMID 35960374 8 citations (Europe PMC) Open-access full textSource: ORCID

  36. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

    Anti-Cancer Drugs, 2023

    DOI 10.1097/cad.0000000000001463 PMID 36729111 5 citations (Europe PMC) Source: ORCID

  37. 230P Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

    ESMO Open, 2023

    DOI 10.1016/j.esmoop.2023.101418 Open-access full textSource: OpenAlex

  38. Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

    Urologia Internationalis, 2023

    DOI 10.1159/000528994 PMID 36996793 3 citations (Europe PMC) Source: ORCID

  39. Comparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.6_suppl.481 Source: OpenAlex

  40. The Prognostic Significance of KIAA1522 Expression in Non-Small-Cell Lung Cancer Patients

    Cureus, 2023

    DOI 10.7759/cureus.44016 PMID 37746394 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  41. Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia

    Cureus, 2023

    DOI 10.7759/cureus.41992 PMID 37492039 3 citations (OpenAlex) Open-access full textSource: OpenAlex

  42. LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study

    Immuno-Oncology Technology, 2023

    DOI 10.1016/j.iotech.2023.100692 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  43. Phenotypic and Genetic Features that Differ Between Hereditary and Sporadic Melanoma: Results of a Preliminary Study from a Single Center from Turkey

    Dermatology Practical & Conceptual, 2023

    DOI 10.5826/dpc.1303a146 PMID 37557112 3 citations (OpenAlex) Open-access full textSource: OpenAlex

  44. Prevalence of EGFR mutations in patients with resected stage I-III non-squamous NSCLC: Results from the EARLY-EGFR study.

    Journal of Clinical Oncology, 2023

    DOI 10.1200/jco.2023.41.16_suppl.8531 Source: OpenAlex

  45. Heart Rate Recovery and Chronotropic Response on Exercise in Colorectal Cancer Survivors

    European Respiratory Journal, 2023

    DOI 10.1183/13993003.congress-2023.pa3398 Source: OpenAlex

  46. P2.06-10 Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

    Journal of Thoracic Oncology, 2023

    DOI 10.1016/j.jtho.2023.09.556 Open-access full textSource: OpenAlex

  47. 600 Objective response impact on patient reported outcomes (PROs) in patients with aNSCLC with PD-L1 ≥50% receiving cemiplimab versus chemotherapy: EMPOWER-Lung 1

    Journal for ImmunoTherapy of Cancer, 2023

    DOI 10.1136/jitc-2023-sitc2023.0600 Open-access full textSource: OpenAlex

  48. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal carcinoma

    Bosnian Journal of Basic Medical Sciences, 2022

    DOI 10.17305/bjbms.2021.7069 PMID 35460397 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  49. The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients

    Pancreas, 2022

    DOI 10.1097/mpa.0000000000002167 PMID 37078939 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  50. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

    Journal of Cancer Research and Clinical Oncology, 2022

    DOI 10.1007/s00432-022-04252-2 PMID 36048274 5 citations (Europe PMC) Open-access full textSource: OpenAlex